There is a version of the psychedelics story that everyone already knows. A veteran who stopped waking up screaming. A cancer patient who made peace with dying. A depressive who, after decades of grey, felt sunlight again. These stories are moving, they are frequently true, and Netflix, bestselling books, presidential press conferences, and a booming investor class have spent the past several years turning them into a single, tidy narrative: psychedelics are the breakthrough that psychiatry has been waiting for.
The trouble is that a good story is not the same thing as good evidence, and 2026 has been a rough year for anyone who assumed the two had already converged.
The Blinding Problem No One Wants to Talk About
Start with the mechanics of a clinical trial. The entire point of a placebo-controlled study is that participants don’t know which arm they’re in — otherwise their expectations, not the drug, start doing the work. That’s straightforward with a pill that produces no noticeable sensation. It is much harder when the “drug” produces vivid hallucinations, ego dissolution, and hours-long emotional catharsis.
A team of Canadian researchers decided to actually check how often this “blinding” was working in psychedelic trials. Reviewing 112 supposedly gold-standard studies of psilocybin, LSD, ketamine, MDMA, and DMT, they found that fewer than a third even bothered to test whether blinding had succeeded — and when they did check, it had failed more than 90 percent of the time for psilocybin, LSD, and DMT, and 85 percent of the time for MDMA. Only ketamine trials fared meaningfully better, because a sedative can plausibly mimic its effects. The researchers, writing in JAMA Psychiatry, concluded the existing trial results should be treated with real skepticism until this is fixed.
That finding landed alongside two more studies that, together, amount to a significant gut-check for the field. A systematic review and meta-analysis by Zachary Williams and colleagues took the radical step of comparing psychedelic-assisted therapy not against a sham placebo pill, but against open-label antidepressants — trials in which patients and doctors both know a real drug is being given, which is functionally what a “blinded” psychedelic trial actually is anyway. Pooling eight psychedelic trials against sixteen open-label antidepressant trials, they found the two produced nearly identical improvement on the standard depression scale — a difference of roughly three-tenths of a point in favor of the antidepressants, well within the margin of chance. In the same week, a separate triple-blind trial of psilocybin for treatment-resistant depression, led by Lea Mertens and funded independently of industry, added another disappointing data point to the pile.
None of this means psychedelics do nothing. It means that when you strip away the placebo-inflating effect of a patient knowing, unmistakably, that they’ve just taken a powerful hallucinogen, the advantage over existing treatments shrinks dramatically — in some analyses, to statistical noise. That is a far cry from “the results are in,” a phrase Michael Pollan used in the Netflix adaptation of his bestseller How to Change Your Mind, and one that critics have pointed out simply isn’t accurate.
How a Book Became a Movement
It’s worth pausing on Pollan specifically, because few individuals illustrate the gap between cultural momentum and scientific caution better than he does. His 2018 book turned psilocybin, MDMA, and LSD into dinner-party conversation for an audience that had previously associated them with Woodstock and burnout. The 2022 docuseries went further: reviewers at the time noted that by showcasing almost exclusively success stories, the show risked leaving casual viewers with the impression that psychedelic therapy is a near-universal cure, when even the most favorable clinical trials typically get only around a third of participants into full remission. One reviewer described the series as playing out like an infomercial for psychedelic-assisted therapy, right down to researchers on camera declaring that the debate was essentially settled.
This is not a minor cultural footnote. It’s the mechanism. Popular science journalism, celebrity podcasts, glossy docuseries, and — as of 2026 — the White House itself have been running well ahead of the peer-reviewed literature, and each layer of amplification tends to strip out the caveats that were present one step back. A tentative Phase 2 signal becomes a magazine feature; the magazine feature becomes a talking point on a wellness podcast; the talking point becomes political testimony. By the time the idea reaches a policymaker or a desperate patient, “shows some promise in small, unblinded trials” has quietly become “the results are in.”
We’ve Run This Experiment Before
Psychiatry has a name for what happens when enthusiasm outruns evidence, because it has happened before — twice, on two continents, in living memory.
The first round was psychedelic research itself. A wave of studies in the 1950s and ’60s explored LSD for alcoholism and neurosis with real optimism, before the research collapsed amid moral panic, sloppy methodology, and the countercultural baggage that men like Timothy Leary attached to it. Researchers today openly acknowledge they’re now roughly as far into the second wave of research as their predecessors got before that first one ground to a halt — which is less a triumphant milestone than an open question about whether history is about to rhyme.
The second round was closer to home and much more recent: Australia’s rollout of medicinal cannabis. Legalized in 2016 under intense public and political pressure, prescriptions exploded from a few hundred to more than a million within less than a decade, generating a market worth hundreds of millions of dollars. According to reporting compiled by the Dalgarno Institute, Australia’s drug regulator fielded more than 600 adverse event reports between mid-2022 and mid-2025 — including dozens involving psychosis, over a dozen involving suicidal ideation, and cases of homicidal ideation — while acknowledging it hadn’t actually investigated the safety of most of the products in question. By late 2025, the country’s peak medical and pharmacy bodies were writing jointly to the health minister to warn about coercive prescribing practices and a system being exploited by commercial interests that had outpaced the regulatory infrastructure meant to contain them.
Then, in February 2023, Australia became the first country in the world to down-schedule psilocybin and MDMA for clinical use — and it did so, according to the same reporting, over the explicit objection of its own expert advisory committee, which had cited the absence of completed Phase III trials, the difficulty of translating tightly controlled research settings into everyday clinical practice, and the fact that no approved psilocybin product existed anywhere on earth. An independent report commissioned to inform that very decision rated the certainty of the evidence as low to very low using the Cochrane GRADE framework. The regulator reversed its own interim caution after a lobbying campaign generated thousands of public submissions — submissions a delegate later noted were largely brief form responses that didn’t engage with the substance of the committee’s concerns at all.
If that sequence sounds familiar, it’s because the United States appears to be running a faster, higher-stakes version of it right now. In April 2026, an executive order directed the FDA and DEA to fast-track psilocybin, MDMA, and ibogaine, committed federal funding, and instructed regulators to establish expedited access pathways ahead of completed Phase III trials. Legal analysts at Harvard’s Petrie-Flom Center noted the political theater surrounding the signing — and pointed out that one company’s product had reportedly been pulled from a priority list and then abruptly reinstated in the same order, a detail that reads less like scientific sequencing than political stagecraft. Shares in psychedelic drug developers jumped on the news.
The inclusion of ibogaine drew particular alarm from researchers, since the compound has documented cardiac risks — including a 2026 study finding it caused clinically significant heart-rhythm prolongation in half of subjects tested, in some cases for more than a day — and has not completed even Phase I trials in the United States.
The Part the Highlight Reel Leaves Out
Beyond the numbers, there is a harder story that rarely makes it into a docuseries. The very quality that makes psychedelics interesting to therapists — the suggestibility and emotional openness they induce — is also what makes patients acutely vulnerable to the people supervising them. The most extensively documented case involves a PTSD trial participant whose sessions, later reviewed by journalists, showed her therapists behaving in ways so far outside professional norms that three related research papers were eventually retracted for ethical violations. That case wasn’t a one-off; the FDA’s 2024 rejection of an MDMA-assisted therapy application cited ongoing concerns about therapist misconduct alongside its concerns about trial design and functional unblinding, and a separate academic paper was later flagged for allegedly downplaying practices described by the therapists it interviewed.
There is also, less dramatically, a straightforward conflicts-of-interest problem. One researcher in the field has remarked that he knows only a single colleague who has never personally used psychedelics — a level of insider enthusiasm that would raise eyebrows in almost any other area of drug development, and one that sits alongside a growing web of consulting fees flowing from psychedelic companies to the researchers publishing on their products.
Caution Is Not the Same as Dismissal
None of this amounts to an argument that psychedelics have no therapeutic value, and it would be its own kind of overreach to claim otherwise. Some trials, imperfect as they are, do show genuine signal, particularly for narrowly defined, carefully screened populations under close supervision — a population and setting that bears little resemblance to how a drug behaves once it’s prescribed at scale. But “promising in small, poorly blinded trials with a devoted research community” is a meaningfully different claim than “a proven, superior alternative to existing psychiatric medication,” and the media apparatus surrounding psychedelics — bestselling books, glossy documentaries, celebrity podcasts, and now executive orders — has spent years collapsing that distinction.
What the evidence currently supports is neither the panacea of the popular narrative nor blanket rejection, but something far less cinematic: the standard, unglamorous machinery of drug regulation — completed Phase III trials, active-comparator designs that account for unblinding, independent committee review insulated from public lobbying campaigns, mandatory long-term safety data, and real structural safeguards against therapist misconduct. That machinery exists precisely because moving individual stories are not, and have never been, a substitute for population-level evidence.
Skipping it hasn’t gone well before. There’s little reason to expect this time to be different simply because the sales pitch has gotten better.
Dalgarno Institute
Sources: Orsini et al., “Blinding Integrity in Psychedelic Randomized Clinical Trials,” JAMA Psychiatry (2026); Williams, Barnett & Szigeti, “Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions,” JAMA Psychiatry (2026); Mertens et al., “Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial,” JAMA Psychiatry (2026); Dalgarno Institute, “The Psychedelic Movement in the US: A Risky Experiment?” (2025) and “When Politics Overrides Science: The Dangerous Rush to Psychedelic Medicine” (2026); Psychedelic Spotlight and Overland literary journal reviews of Netflix’s How to Change Your Mind (2022); additional reporting via Science Media Centre, Drug Discovery Trends, Petrie-Flom Center (Harvard Law), and Medical Xpress.